TOWARDS PERSONALIZED MEDICINE USING A NOVEL PRECLINICAL MODEL: IDENTIFYING DARATUMUMAB AS EFFECTIVE TREATMENT FOR MULTIPLE MYELOMA

被引：0
|
作者：
Noort, W. [1 ]
Groen, R. [1 ]
Raymakers, R. [1 ]
Prins, H. [1 ]
Aalders, L. [1 ]
Hofhuis, F. [1 ]
van Kessel, B. [1 ]
Moerer, P. [1 ]
Rozemuller, H. [1 ]
de Bruijn, J. [2 ]
de Weers, M. [3 ]
Schuringa, J. [1 ]
Parren, P. [3 ]
Lokhorst, H. [1 ]
Mutis, T. [1 ]
Martens, A. [1 ]
机构：
[1] Univ Med Ctr, Utrecht, Netherlands
[2] Queen Mary Univ London, Sch Engn & Mat Sci, London, England
[3] Genmab BV, Utrecht, Netherlands
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1075
引用
收藏
页码：438 / 438
页数：1
相关论文
共 50 条
  • [1] Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development
    Phipps, Colin
    Chen, Yunxin
    Gopalakrishnan, Sathish
    Tan, Daryl
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (03) : 120 - 127
  • [2] Preclinical Activity of JNJ-7957, a Novel BCMAxCD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
    Frerichs, Kristine A.
    Broekmans, Marloes E. C.
    Soto, Jhon A. Marin
    van Kessel, Berris
    Heymans, Martijn W.
    Holthof, Lisa C.
    Verkleij, Christie P. M.
    Boominathan, Rengasamy
    Vaidya, Bhavesh
    Sendecki, Jocelyn
    Axel, Amy
    Gaudet, Francois
    Pillarisetti, Kodandaram
    Zweegman, Sonja
    Adams, Homer C., III
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    CLINICAL CANCER RESEARCH, 2020, 26 (09) : 2203 - 2215
  • [3] Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients
    Schueler, Julia B.
    Wider, Dagmar
    Klingner, Kerstin
    Siegers, Gabrielle Melanie
    May, Annette M.
    Waldschmidt, Johannes M.
    Keller, Alexander
    Duyster, Justus
    Waesch, Ralph M.
    Engelhardt, Monika
    BLOOD, 2015, 126 (23)
  • [4] Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model
    van Nieuwenhuijzen, Niels
    Cuenca, Marta
    Abbink, Leonie
    Jak, Margot
    Peperzak, Victor
    Minnema, Monique C.
    EJHAEM, 2024, 5 (01): : 141 - 146
  • [5] Towards Identifying of Effective Personalized Antihypertensive Treatment Rules from Electronic Health Records Data Using Classification Methods: Initial Model
    Semakova, Anna
    Zvartau, Nadezhda
    Bochenina, Klavdiya
    Konradi, Aleksandra
    CENTERIS 2017 - INTERNATIONAL CONFERENCE ON ENTERPRISE INFORMATION SYSTEMS / PROJMAN 2017 - INTERNATIONAL CONFERENCE ON PROJECT MANAGEMENT / HCIST 2017 - INTERNATIONAL CONFERENCE ON HEALTH AND SOCIAL CARE INFORMATION SYSTEMS AND TECHNOLOGIES, CENTERI, 2017, 121 : 852 - 858
  • [6] Pharmacogenetic development of personalized medicine: Multiple sclerosis treatment as a model
    Kirstein-Grossman, I
    Beckmann, JS
    Lancet, D
    Miller, A
    DRUG NEWS & PERSPECTIVES, 2002, 15 (09) : 558 - 567
  • [7] Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma
    Amodio, Nicola
    Di Martino, Maria Teresa
    Neri, Antonino
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 : S125 - S137
  • [8] Landmark study and novel technology encourage advancement in personalized multiple myeloma treatment
    Miller, Sarah
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (12) : 1788 - 1788
  • [9] Landmark study and novel technology encourage advancement in personalized multiple myeloma treatment
    不详
    PERSONALIZED MEDICINE, 2011, 8 (06) : 603 - 604
  • [10] Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab
    van der Veer, Michael S.
    de Weers, Michel
    van Kessel, Berris
    Wittebol, Shulamiet
    Bakker, Joost M.
    Parren, Paul W. H. I.
    Lokhorst, Henk M.
    Mutis, Tuna
    BLOOD, 2010, 116 (21) : 1262 - 1262
12345